Sugi Predict

Sugi Predict / Compounds / SCHEMBL83486

SCHEMBL83486

SCHEMBL83486

BrCc1c2ccccc2cc2c1ccc1ccccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.56
▸ HSD17B10 Q99714 4/20 0.56
▸ CYP1B1 Q16678 2/20 0.56
▸ HIF1A Q16665 1/20 0.56
▸ HPRT1 P00492 4/20 0.48
▸ CYP2A6 P11509 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ HTR2A P28223 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ CYP1A2 P05177 6/20 0.41
▸ FYN P06241 2/20 0.41
▸ ACHE P22303 2/20 0.41
▸ AHR P35869 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ ERBB2 P04626 1/20 0.41
▸ MAOA P21397 1/20 0.41
▸ MAPT P10636 3/20 0.41
▸ HPGD P15428 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL337526 0.98 ALDH1A1 (0.54) ALDH1A1HSD17B10CYP1B1HIF1AHPRT1
SCHEMBL29516177 0.83 HTR2A (0.60) ALDH1A1HSD17B10CYP1B1HIF1ACYP2A6
SCHEMBL118514 0.83 HTR2A (0.60) ALDH1A1HSD17B10CYP1B1HIF1ACYP2A6
SCHEMBL3343719 0.81 ALDH1A1 (0.56) ALDH1A1HSD17B10CYP1B1HIF1AHPRT1
SCHEMBL19065039 0.81 L3MBTL1 (0.70) ALDH1A1HSD17B10CYP1B1HIF1AHPRT1
SCHEMBL5665402 0.79 ALDH1A1 (0.54) ALDH1A1HSD17B10CYP1B1HIF1AHPRT1
SCHEMBL2312432 0.78 ALDH1A1 (0.52) ALDH1A1HSD17B10CYP1B1HIF1AHPRT1
SCHEMBL12627467 0.77 ALDH1A1 (0.50) ALDH1A1HSD17B10CYP1B1HIF1AHPRT1
SCHEMBL14559256 0.77 ALDH1A1 (0.50) ALDH1A1HSD17B10CYP1B1HIF1AHPRT1
SCHEMBL17183136 0.76 ALDH1A1 (0.54) ALDH1A1HSD17B10CYP1B1HIF1AHPRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 399 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339991-A1 HYPOXIA-ACTIVATED DNA ALKYLATING AGENT AND MEDICAL USE THEREOF ASCENTAWITS PHARMACEUTICALS, LTD. (CN) 2023-10-26 — — US disclosed
EP-4212538-A1 HYPOXIA-ACTIVATED DNA ALKYLATING AGENT AND MEDICAL USE THEREOF Ascentawits Pharmaceuticals, Ltd. (CN) 2023-07-19 — — EP disclosed
US-20230026163-A1 ANTICANCER COMPOUND AND MEDICAL USE THEREOF ASCENTAWITS PHARMACEUTICALS, LTD. (CN) 2023-01-26 — — US disclosed
EP-4079738-A1 ANTICANCER COMPOUND AND MEDICAL USE THEREOF Ascentawits Pharmaceuticals, Ltd. (CN) 2022-10-26 — — EP disclosed
WO-2022052564-A1 HYPOXIA-ACTIVATED DNA ALKYLATING AGENT AND MEDICAL USE THEREOF 深圳艾欣达伟医药科技有限公司 2022-03-17 — — WO disclosed
CN-113789316-A Phytases, nucleic acids encoding them and methods of making and using them 巴斯夫酶有限责任公司 2021-12-14 — — CN disclosed
CN-106222185-B Glucanases, nucleic acids encoding them and methods of making and using them 维莱尼姆公司 2021-12-03 — — CN disclosed
CN-104450754-B Phytases, nucleic acids encoding them and methods of making and using them 巴斯夫酶有限责任公司 2021-10-01 — — CN disclosed
CN-110577945-A xylanases, nucleic acids encoding them, and methods for making and using them 维莱尼姆公司 2019-12-17 — — CN disclosed
US-10428340-B2 Phytases, nucleic acids encoding them and methods for making and using them SYNGENTA PARTICIPATIONS AG (CH) 2019-10-01 — — US disclosed
EP-0286898-B1 Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same ENZO BIOCHEM INC (US) 1998-04-29 — — EP disclosed
EP-0618228-A1 Protein with a moiety capable of chelating ions attached thereto ENZO BIOCHEM, INC. (US) 1994-10-05 — — EP disclosed
US-5260433-A Nonradioactive ENZO DIAGNOSTICS, INC. (US) 1993-11-09 — — US disclosed
US-5241060-A Base moiety-labeled detectable nucleatide ENZO DIAGNOSTICS, INC. (US) 1993-08-31 — — US disclosed
EP-0302175-A2 Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same ENZO BIOCHEM, INC. (US) 1989-02-08 — — EP disclosed
EP-0286898-A2 Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same ENZO BIOCHEM, INC. (US) 1988-10-19 — — EP disclosed
EP-0285950-A2 A drug delivery conjugate ENZO BIOCHEM, INC. (US) 1988-10-12 — — EP disclosed
EP-0285058-A2 Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same ENZO BIOCHEM, INC. (US) 1988-10-05 — — EP disclosed
EP-0285057-A2 Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same ENZO BIOCHEM, INC. (US) 1988-10-05 — — EP disclosed
EP-0097373-A2 Modified labeled nucleotides and polynucleotides and methods of preparing, utilizing and detecting same ENZO BIOCHEM, INC. (US) 1984-01-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339991-A1 HYPOXIA-ACTIVATED DNA ALKYLATING AGENT AND MEDICAL USE THEREOF HIF1AN, HIF1A, MGMT ALDH1A1 1217/4885HSD17B10 3277/4885CYP1B1 2742/4885
US-20230026163-A1 ANTICANCER COMPOUND AND MEDICAL USE THEREOF SLCO1B1, SLCO1B3, VHL ALDH1A1 523/4885HSD17B10 585/4885CYP1B1 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.